Ocera Therapeutics, Inc. (OCRX) Downgraded by Zacks Investment Research
Zacks Investment Research lowered shares of Ocera Therapeutics, Inc. (NASDAQ:OCRX) from a hold rating to a sell rating in a research report report published on Wednesday morning.
According to Zacks, “Ocera Therapeutics, Inc. is a biopharmaceutical company. It focused on the development and commercialization of proprietary compounds to treat acute and chronic orphan liver diseases. Ocera Therapeutics, Inc., formerly known as Tranzyme, Inc., is based in San Diego, California. “
Separately, HC Wainwright downgraded Ocera Therapeutics from a buy rating to a neutral rating and set a $1.75 target price on the stock. in a research report on Friday, November 3rd. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and one has assigned a buy rating to the company’s stock. Ocera Therapeutics has an average rating of Hold and an average price target of $1.69.
Ocera Therapeutics (NASDAQ OCRX) remained flat at $$1.71 during midday trading on Wednesday. 508,400 shares of the company traded hands, compared to its average volume of 1,169,978. Ocera Therapeutics has a one year low of $0.52 and a one year high of $2.95.
An institutional investor recently raised its position in Ocera Therapeutics stock. Hikari Power Ltd increased its stake in shares of Ocera Therapeutics, Inc. (NASDAQ:OCRX) by 50.6% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 376,596 shares of the biopharmaceutical company’s stock after purchasing an additional 126,596 shares during the quarter. Hikari Power Ltd owned 1.42% of Ocera Therapeutics worth $437,000 at the end of the most recent quarter. Institutional investors own 20.22% of the company’s stock.
Ocera Therapeutics Company Profile
Ocera Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ocera Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocera Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.